In the patients with BCLM, patients in the high-risk group had a significantly higher expression level of MAP3K13. High MAP3K13 expression was reported to be correlated with poor prognosis in breast cancers, which might be one of the reasons that a shorter survival time was observed in the high-risk group of our study [25]. The gene discussed is MAP3K13; the disease is breast cancer.